The AD1 and AD2 Transactivation Domains of E2A Are Essential for the Antiapoptotic Activity of the Chimeric Oncoprotein E2A-HLF

ABSTRACT The chimeric oncoprotein E2A-HLF, generated by the t(17;19) chromosomal translocation in pro-B-cell acute lymphoblastic leukemia, incorporates the transactivation domains of E2A and the basic leucine zipper (bZIP) DNA-binding and protein dimerization domain of HLF (hepatic leukemic factor). The ability of E2A-HLF to prolong the survival of interleukin-3 (IL-3)-dependent murine pro-B cells after IL-3 withdrawal suggests that it disrupts signaling pathways normally responsible for cell suicide, allowing the cells to accumulate as transformed lymphoblasts. To determine the structural motifs that contribute to this antiapoptotic effect, we constructed a panel of E2A-HLF mutants and programmed their expression in IL-3-dependent murine pro-B cells (FL5.12 line), using a zinc-inducible vector. Neither the E12 nor the E47 product of the E2A gene nor the wild-type HLF protein was able to protect the cells from apoptosis induced by IL-3 deprivation. Surprisingly, different combinations of disabling mutations within the HLF bZIP domain had little effect on the antiapoptotic property of the chimeric protein, so long as the amino-terminal portion of E2A remained intact. In the context of a bZIP domain defective in DNA binding, mutants retaining either of the two transactivation domains of E2A were able to extend cell survival after growth factor deprivation. Thus, the block of apoptosis imposed by E2A-HLF in pro-B lymphocytes depends critically on the transactivating regions of E2A. Since neither DNA binding nor protein dimerization through the bZIP domain of HLF is required for this effect, we propose mechanisms whereby protein-protein interactions with the amino-terminal region of E2A allow the chimera to act as a transcriptional cofactor to alter the expression of genes regulating the apoptotic machinery in pro-B cells.

[1]  A T Look,et al.  Oncogenic transcription factors in the human acute leukemias. , 1997, Science.

[2]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[3]  Kevin S. Smith,et al.  Chimeric oncoprotein E2a-Pbx1 induces apoptosis of hematopoietic cells by a p53-independent mechanism that is suppressed by Bcl-2 , 1997, Oncogene.

[4]  J L Cleveland,et al.  Pivotal role for the NFIL3/E4BP4 transcription factor in interleukin 3-mediated survival of pro-B lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Look,et al.  Cell transformation mediated by homodimeric E2A-HLF transcription factors , 1997, Molecular and cellular biology.

[6]  A. Feeney,et al.  Both E12 and E47 allow commitment to the B cell lineage. , 1997, Immunity.

[7]  M. Cleary,et al.  The Hox cooperativity motif of the chimeric oncoprotein E2a-Pbx1 is necessary and sufficient for oncogenesis , 1997, Molecular and cellular biology.

[8]  H. Horvitz,et al.  Transcriptional regulator of programmed cell death encoded by Caenorhabditis elegans gene ces-2 , 1996, Nature.

[9]  A. Look,et al.  Reversal of apoptosis by the leukaemia-associated E2A–HLF chimaeric transcription factor , 1996, Nature.

[10]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[11]  M. Cleary,et al.  The proto-oncogene HLF and the related basic leucine zipper protein TEF display highly similar DNA-binding and transcriptional regulatory properties. , 1996, Blood.

[12]  Q. Lu,et al.  Structural determinants within Pbx1 that mediate cooperative DNA binding with pentapeptide-containing Hox proteins: proposal for a model of a Pbx1-Hox-DNA complex , 1996, Molecular and cellular biology.

[13]  S. Hunger,et al.  Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. , 1996, Blood.

[14]  Q. Lu,et al.  DNA-binding by oncoprotein E2a-Pbx1 is important for blocking differentiation but dispensable for fibroblast transformation. , 1996, Oncogene.

[15]  P. Jennings,et al.  The AD1 transactivation domain of E2A contains a highly conserved helix which is required for its activity in both Saccharomyces cerevisiae and mammalian cells , 1996, Molecular and cellular biology.

[16]  C. Murre,et al.  The hexapeptide LFPWMR in Hoxb-8 is required for cooperative DNA binding with Pbx1 and Pbx2 proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[17]  T. Kadesch,et al.  B-cell-specific DNA binding by an E47 homodimer , 1995, Molecular and cellular biology.

[18]  J. Cleveland,et al.  c-Myc and apoptosis. , 1995, Biochimica et biophysica acta.

[19]  C. Murre,et al.  Hox gene products modulate the DNA binding activity of Pbx1 and Pbx2 , 1995, Mechanisms of Development.

[20]  T. Inaba,et al.  E2A-HLF-mediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF , 1995, Molecular and cellular biology.

[21]  G. Lyons,et al.  Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation during mouse embryogenesis. , 1995, Development.

[22]  M. Cleary,et al.  Pbx proteins display hexapeptide-dependent cooperative DNA binding with a subset of Hox proteins. , 1995, Genes & development.

[23]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[24]  S. Orkin,et al.  Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL , 1995, Nature.

[25]  Ian Krop,et al.  E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements , 1994, Cell.

[26]  H. Weintraub,et al.  The helix-loop-helix gene E2A is required for B cell formation , 1994, Cell.

[27]  D. LeBrun,et al.  Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable , 1994, Molecular and cellular biology.

[28]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[29]  R. Pepperkok,et al.  Regulation of G1 progression by E2A and Id helix‐loop‐helix proteins. , 1994, The EMBO journal.

[30]  J R Matthews,et al.  Structure and function of helix-loop-helix proteins. , 1994, Biochimica et biophysica acta.

[31]  F. Lee,et al.  The E2A and tal-1 helix-loop-helix proteins associate in vivo and are modulated by Id proteins during interleukin 6-induced myeloid differentiation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Hsu,et al.  Positive and negative transcriptional control by the TAL1 helix-loop-helix protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Cleary,et al.  Two types of genomic rearrangements create alternative E2A-HLF fusion proteins in t(17;19)-ALL. , 1994, Blood.

[34]  T. Inaba,et al.  DNA-binding specificity and trans-activating potential of the leukemia-associated E2A-hepatic leukemia factor fusion protein , 1994, Molecular and cellular biology.

[35]  M. Cleary,et al.  Bcl2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells. , 1994, Blood.

[36]  David J. Anderson,et al.  Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons , 1993, Cell.

[37]  David P. LeBrun,et al.  Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice , 1993, Cell.

[38]  B. Spiegelman,et al.  ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation , 1993, Molecular and cellular biology.

[39]  R. Baler,et al.  Synergistic activation of transcription is mediated by the N-terminal domain of Drosophila fushi tarazu homeoprotein and can occur without DNA binding by the protein , 1993, Molecular and cellular biology.

[40]  C. Murre,et al.  A new transcriptional-activation motif restricted to a class of helix-loop-helix proteins is functionally conserved in both yeast and mammalian cells , 1993, Molecular and cellular biology.

[41]  M. Cleary,et al.  Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. , 1992, Genes & development.

[42]  S. Korsmeyer.  Bcl-2 initiates a new category of oncogenes: regulators of cell death. , 1992, Blood.

[43]  S. Raimondi,et al.  Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. , 1992, Science.

[44]  C. Ingles,et al.  Homeodomain-independent activity of the fushi tarazu polypeptide in Drosophila embryos , 1992, Nature.

[45]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[46]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[47]  L. Swanson,et al.  TEF, a transcription factor expressed specifically in the anterior pituitary during embryogenesis, defines a new class of leucine zipper proteins. , 1991, Genes & development.

[48]  E. Olson,et al.  Inefficient homooligomerization contributes to the dependence of myogenin on E2A products for efficient DNA binding , 1991, Molecular and cellular biology.

[49]  H. Hsu,et al.  Enhancer-binding activity of the tal-1 oncoprotein in association with the E47/E12 helix-loop-helix proteins , 1991, Molecular and cellular biology.

[50]  S. Korsmeyer,et al.  Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. , 1990, Journal of immunology.

[51]  Harold Weintraub,et al.  The protein Id: A negative regulator of helix-loop-helix DNA binding proteins , 1990, Cell.

[52]  D. Lockshon,et al.  MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer , 1989, Cell.

[53]  Y. Jan,et al.  Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence , 1989, Cell.

[54]  David Baltimore,et al.  A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins , 1989, Cell.

[55]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[56]  M. Rosenfeld,et al.  Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain , 1988, Cell.

[57]  A. W. Harris,et al.  The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice , 1986, Cell.

[58]  J. Sklar,et al.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. McCubrey,et al.  Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[60]  C. Croce,et al.  The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. , 1985, Science.

[61]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.